- Home
- USEA vs PHGE Comparison
USEA vs PHGE Comparison
Compare USEA & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- PHGE
- Stock Information
- Founded
- USEA 2004
- PHGE 2015
- Country
- USEA Greece
- PHGE Israel
- Employees
- USEA N/A
- PHGE N/A
- Industry
- USEA Marine Transportation
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- USEA Consumer Discretionary
- PHGE Health Care
- Exchange
- USEA Nasdaq
- PHGE Nasdaq
- Market Cap
- USEA 15.6M
- PHGE 15.5M
- IPO Year
- USEA N/A
- PHGE N/A
- Fundamental
- Price
- USEA N/A
- PHGE N/A
- Analyst Decision
- USEA
- PHGE Strong Buy
- Analyst Count
- USEA 0
- PHGE 1
- Target Price
- USEA N/A
- PHGE $15.00
- AVG Volume (30 Days)
- USEA 23.4K
- PHGE 380.3K
- Earning Date
- USEA 11-25-2025
- PHGE 11-13-2025
- Dividend Yield
- USEA 2.40%
- PHGE N/A
- EPS Growth
- USEA N/A
- PHGE N/A
- EPS
- USEA N/A
- PHGE N/A
- Revenue
- USEA $42,625,000.00
- PHGE N/A
- Revenue This Year
- USEA N/A
- PHGE N/A
- Revenue Next Year
- USEA N/A
- PHGE N/A
- P/E Ratio
- USEA N/A
- PHGE N/A
- Revenue Growth
- USEA N/A
- PHGE N/A
- 52 Week Low
- USEA $1.00
- PHGE $0.34
- 52 Week High
- USEA $2.48
- PHGE $1.16
- Technical
- Relative Strength Index (RSI)
- USEA 48.82
- PHGE 64.60
- Support Level
- USEA $1.61
- PHGE $0.57
- Resistance Level
- USEA $1.75
- PHGE $0.65
- Average True Range (ATR)
- USEA 0.06
- PHGE 0.04
- MACD
- USEA -0.01
- PHGE 0.01
- Stochastic Oscillator
- USEA 42.86
- PHGE 87.23
About USEA United Maritime Corporation
United Maritime Corp is an international shipping company. It is engaged in seaborne transportation services. The group currently operates a fleet of seven dry bulk vessels, comprising three Panamax, two Capesize and two Kamsarmax vessels with an aggregate cargo-carrying capacity of approximately 750,758 dwt.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).